(Q42796997)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21091142%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

title

Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21091142%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

main subject

chronic myeloid leukemia

0 references

1 reference

1 reference

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21091142%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Giuseppe Saglio

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21091142%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

author name string

Francis J Giles

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21091142%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Photis Beris

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21091142%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Richard E Clark

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21091142%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Philipp le Coutre

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21091142%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Francois-Xavier Mahon

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21091142%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Juan-Luis Steegmann

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21091142%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Gianantonio Rosti

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21091142%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

publication date

9 November 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21091142%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Hematology

16 January 2020

number of pages

9

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21091142%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

volume

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21091142%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21091142%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

665-673

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21091142%20AND%20SRC:MED&resulttype=core&format=json

Chronic myeloid leukemia: reversing the chronic phase.

16 January 2020

cites work

1 reference

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 January 2018

1 reference

Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: comparative safety profiles of newer agents

21 January 2018

1 reference

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

21 January 2018

1 reference

Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia

21 January 2018

1 reference

Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia

21 January 2018

1 reference

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

21 January 2018

1 reference

Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy.

21 January 2018

1 reference

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia

21 January 2018

1 reference

Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase

21 January 2018

1 reference

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors

21 January 2018

1 reference

UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/EHM.10.61

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21091142%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference